Saturday 17 October 2026 Export CVM’s income statement to Excel — free account

Cel-Sci Corporation

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%

Follow CVM

Alert me

Market cap: $30.6M
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: —
F-score: 4/9
Altman Z: −1.64
Beneish M: −2.35
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.87

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	1	1	—	—	—	2	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 30.61

Revenue 0.56

Net Income (22.70)

Free Cash Flow (16.75)

Net Debt (2.74)

Current Ratio 1.48

Debt/Equity 0.35

P/E ratio 0.00

Fwd P/E (12.20)

P/S ratio 38.82

P/B ratio 1.98

Past 5Y EPS Growth —

This Y EPS Growth (16.20%)

Next Y EPS Growth 22.39%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 25.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 7.78%

10-year low 10-year high

P/B against its own 10 years 9.47%

10-year low 10-year high

EV/Sales against its own 10 years 5.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	5	11	7
Receivables	—	—	—	—
Inventory	2	1	0	0
Other	0	0	0	0
	7	6	12	8

	2023	2024	2025	Q'26
Payables	2	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	6	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	21.44%	16.18%	25.14%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(4.15%)	(20.84%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	—	—	—	—	—
’20	0	0	0	0	1
’19	0	0	0	0	0
’18	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(4)	(4)	(4)	—	—
’25	(4)	(4)	(4)	(5)	(17)
’24	(5)	(5)	(5)	(5)	(19)
’23	(5)	(7)	(6)	(5)	(23)
’22	(5)	(3)	(6)	(5)	(18)
’21	(4)	(5)	(5)	(5)	(19)
’20	(4)	(4)	(4)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(4)	(4)	(4)	—	—
’25	(4)	(4)	(4)	(5)	(17)
’24	(5)	(5)	(5)	(5)	(19)
’23	(5)	(8)	(6)	(5)	(23)
’22	(5)	(3)	(6)	(5)	(19)
’21	(7)	(8)	(7)	(5)	(28)
’20	(4)	(5)	(5)	(5)	(18)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.68)	(0.67)	(0.47)	—	—
’25	(3.30)	(2.40)	(1.36)	0.68	(6.27)
’24	(4.20)	(4.20)	(4.20)	(2.70)	(15.31)
’23	(5.41)	(5.71)	(5.71)	(4.80)	(21.92)
’22	(6.01)	(6.91)	(6.91)	(6.31)	(26.13)
’21	(6.31)	(8.41)	(7.51)	(5.71)	(27.93)
’20	(4.80)	(7.51)	(8.11)	(4.20)	(24.62)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	45.00	43.80	24.60	71.10	190.50	211.80	56.40	31.20	11.10	1.98	Analyst estimates 2026–2028 Powerpack
	High	495.00	135.00	133.20	297.90	540.00	1,227.30	231.90	99.90	92.40	20.40
People
People	Employees	—	—	—	—	—	—	—	—	—	—
	Revenue/emp, $m	0.00	—	0.00	0.00	0.00	—	—	—	—	—
Income, $m
Income, $m	Revenue	0	—	0	0	1	—	—	—	—	—
	Gross margin, %	100.00	0.00	100.00	100.00	100.00	0.00	0.00	0.00	—	—
	EBT	(12)	(14)	(32)	(22)	(30)	(36)	(37)	(32)	(27)	(25)
	EBT margin, %	(4,038.06)	0.00	(6,680.07)	(4,782.76)	(5,415.30)	0.00	0.00	0.00	0.00	0.00
	Net income	(12)	(14)	(32)	(22)	(30)	(36)	(37)	(32)	(27)	(25)
	Depreciation	1	2	3	1	2	2	4	4	4	4
Per share, $
Per share, $	Revenue	1.76	0.00	0.84	0.45	0.46	0.00	0.00	0.00	0.00	0.00
	Earnings	(67.57)	(54.95)	(56.16)	(21.32)	(24.62)	(27.03)	(26.13)	(21.92)	(15.31)	(6.27)
	Cash flow	(142.48)	(52.48)	(23.64)	(15.72)	(12.48)	(13.88)	(12.69)	(15.43)	(10.44)	(4.22)
	Capex	(0.21)	(0.06)	(0.10)	(0.32)	(2.20)	(6.68)	(0.46)	(0.25)	(0.06)	(0.01)
	Free cash flow	(142.70)	(52.55)	(23.75)	(16.05)	(14.68)	(20.55)	(13.15)	(15.68)	(10.50)	(4.23)
	Book value	(4.19)	(12.70)	0.00	4.95	16.12	41.75	22.38	8.92	7.14	3.93
	Shares, m	0	0	1	1	1	1	1	1	2	4
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	0.00	0.00	—	—	—	—	—
	P/S	132.11	—	151.85	601.73	838.05	—	—	—	—	—
	P/B	0.00	—	80,414.60	54.23	23.74	—	—	—	—	—
	EV/Sales	171.39	—	160.61	615.05	833.24	—	—	—	—	—
	EV/FCF	(2.11)	—	(5.69)	(17.09)	(25.90)	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(23)	(14)	(13)	(16)	(15)	(19)	(18)	(23)	(19)	(17)
	Capex	0	0	0	0	(3)	(9)	(1)	0	0	0
	Free cash flow	(23)	(14)	(13)	(17)	(18)	(28)	(19)	(23)	(19)	(17)
Balance, $m
Balance, $m	Working capital	1	(7)	2	7	13	41	21	1	1	6
	Total debt	13	13	13	14	12	13	12	10	8	6
	Net debt	10	11	3	5	(4)	(29)	(11)	6	3	(5)
	Shareholders’ equity	(1)	(3)	0	5	20	57	32	13	13	16
Returns, %
Returns, %	ROA	(43.09)	(60.35)	(121.31)	(77.38)	(88.84)	(63.08)	(59.54)	(79.86)	(95.90)	(92.16)
	ROIC	(157.00)	(178.26)	(341.36)	(123.78)	(113.43)	(82.04)	(106.25)	(103.44)	(102.38)	(145.08)
	ROE	423.14	718.45	1,909.51	(862.17)	(243.58)	(96.28)	(84.85)	(142.65)	(211.49)	(176.32)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2020 · latest quarter Sep 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ALGS Aligos Therapeutics, Inc.	$33.7M	— (loss-making)	— (loss-making)	+2,778.55% (above 0%: growing)	n/m	−59.81% (below 0%: shrinking)	100.00%	(6.80%)	Compare
ATNM Actinium Pharmaceuticals, Inc.	$33.3M	3.1×	— (loss-making)	+77,677.78% (above 0%: growing)	n/m	−4.91% (below 0%: shrinking)	100.00%	78.76%	Compare
BCTX BRIACELL THERAP	$32.8M	1.5×	—	—	n/m	+0.21% (above 0%: growing)	0.00%	0.00%	Compare
GNTA Genenta Science S.p.A. Unsponsored ADR	$32.3M	—	—	—	—	+35.94% (above 0%: growing)	0.00%	—	Compare
MGX Metagenomi Therapeutics, Inc.	$31.9M	— (loss-making)	— (loss-making)	−103.02% (below 0%: shrinking)	n/m	+7.98% (above 0%: growing)	100.00%	11,195.72%	Compare
GRDX GridAI Technologies Corp.	$31.8M	— (loss-making)	—	—	n/m	−2,640.98% (below 0%: shrinking)	(42.49%)	(15,258.21%)	Compare
NXTC NextCure, Inc.	$31.5M	— (loss-making)	— (loss-making)	+1,549.08% (above 0%: growing)	n/m	+57.23% (above 0%: growing)	0.00%	0.00%	Compare
CVM Cel-Sci Corporation	$30.6M	— (loss-making)	— (loss-making)	−62.66% (below 0%: shrinking)	n/m	−2.33% (below 0%: shrinking)	0.00%	0.00%
RNAZ TransCode Therapeutics Inc.	$30.5M	— (loss-making)	—	—	n/m	−28.79% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$32.1M	—	—	+2,163.82%	—	−2.35%	0.00%	0.00%

All 614 Biotechnology stocks →

Cel-Sci Corporation (CVM) key facts

Cel-Sci Corporation (CVM) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, CVM traded at $1.79, a market capitalization of $30.6 million.
Return on equity was −176.3% and debt-to-equity 0.35.

Source: company filings (standardised) and stockrow calculations.